Dengue vaccine safety checked in pregnant women

NCT ID NCT04486638

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks 500 pregnant women in the US who received the Dengvaxia dengue vaccine. Researchers will monitor mothers and their babies for any side effects or pregnancy complications. The goal is to gather safety data, not to test the vaccine's effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Dengue Tetravalent Vaccine, Live (Dengvaxia)

What this could lead to

If this study finds no safety problems, it could provide reassurance about using Dengvaxia during pregnancy.

What could go wrong

This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may take years and depend on voluntary reporting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENGUE VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site

    RECRUITING

    San Juan, Puerto Rico